Develops radiopharmaceuticals for cancer and Alzheimer's disease.
Jun 2026Revenue $1.56B/yrExpenses $1.25B/yr
No trend
Figures by year
Is Lantheus Holdings profitable?
Yes. In the 12 months to Jun 2026, revenue was $1.56B and expenses $1.25B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.54B | $1.23B | $311M |
| Dec 2024 | $1.53B | $1.08B | $457M |
| Dec 2023 | $1.30B | $932M | $365M |
| Dec 2022 | $935M | $899M | $36.2M |
| Dec 2021 | $425M | $486M | −$60.8M |
| Dec 2020 | $339M | $344M | −$4.20M |
| Dec 2019 | $347M | $296M | $51.7M |
| Dec 2018 | $343M | $279M | $64.5M |
| Dec 2017 | $331M | $280M | $51.9M |
| Dec 2016 | $302M | $245M | $56.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.